mevastatin has been researched along with Diabetic Feet in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egger, AN; Glinos, GD; Jozic, I; Kirsner, RS; Pastar, I; Sawaya, AP; Stojadinovic, O; Stone, RC; Tomic-Canic, M | 1 |
| Davis, SC; Gil, J; Kirsner, RS; Lazovic, S; Pastar, I; Sawaya, AP; Stojadinovic, O; Tomic-Canic, M | 1 |
2 other study(ies) available for mevastatin and Diabetic Feet
| Article | Year |
|---|---|
Mevastatin promotes healing by targeting caveolin-1 to restore EGFR signaling.
Topics: Animals; Caveolin 1; Cell Movement; Cell Proliferation; Diabetic Foot; Disease Models, Animal; ErbB Receptors; Female; Humans; Keratinocytes; Lovastatin; Phenotype; Signal Transduction; Skin; Swine; Wound Healing | 2019 |
Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the glucocorticoid receptor and the long non-coding RNA Gas5.
Topics: Administration, Topical; Diabetic Foot; Gene Expression Regulation; Humans; Keratinocytes; Lovastatin; Proto-Oncogene Proteins c-myc; Receptors, Glucocorticoid; RNA, Long Noncoding; Wound Healing | 2018 |